The Current Advances in Design Strategy (Indirect Strategy and Direct Strategy) for Type‐I Photosensitizers DOI Creative Commons
Ning Ma,

Junjie Wang,

Hui Tang

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 25, 2024

Type-I photosensitizers (PSs) are among the most potential candidates for photodynamic therapy (PDT), as their low dependence on oxygen endow them with many advantages treating hypoxic tumor. However, of reported type-I PSs have a contingency molecular design, because electron transfer (ET) reaction is more difficult to achieve than energy (EET) process. Therefore, it urgent understand design mechanisms PSs. In this review, two ways PSs, i.e., inhibiting EET process (type-II) or enhancing ET (type-I), detailly explained. response, current strategies summarized from perspectives: indirect strategy (inhibiting process: reducing lowest triplet excited state (T

Language: Английский

Evolution of nMOFs in photodynamic therapy: from porphyrins to chlorins and bacteriochlorins for better efficacy DOI Creative Commons
Yutao Zou, Jiayi Chen, Yingli Qu

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 18, 2025

Photodynamic therapy (PDT) has gained significant attention due to its non-invasive nature, low cost, and ease of operation. Nanoscale metal-organic frameworks (nMOFs) incorporating porphyrins, chlorins, bacteriochlorins have emerged as one the most prominent photoactive materials for tumor PDT. These nMOFs could enhance water solubility, stability loading efficiency photosensitizers (PSs). Their highly ordered porous structure facilitates O2 diffusion enhances generation 1O2 from hydrophobic bacteriochlorins, thereby improving their efficacy phototherapy. This review provides insights into PDT effects derived bacteriochlorins. It overviews design strategies, types reactive oxygen species (ROS), ROS efficiency, unique biological processes involved in inhibiting cell proliferation, focusing on mechanism by which molecular leads enhanced photochemical properties. Finally, highlights new possibilities offered bacteriochlorins-based PDT, emphasizing how optimized can further improve bioapplication porphyrin derivatives represented PSs. With ongoing research technological advancements, we anticipate that this will garner increased scientific researchers toward porphyrin-based nMOFs, elevating potential a approach treatment malignant tumors.

Language: Английский

Citations

0

Recent Progress of Molecular Design in Organic Type I Photosensitizers DOI
Tao Xiong, Yingchao Chen, Mingle Li

et al.

Small, Journal Year: 2025, Volume and Issue: unknown

Published: April 26, 2025

Abstract Photodynamic therapy (PDT) represents a high‐efficient and non‐invasive therapeutic modality for current future tumor treatments, drawing extensive attention in the fields of antitumor drug clinical phototherapy. In recent years, photosensitizer (PS) market PDT applications have expanded to address various cancers skin diseases. However, hypoxic environment within tumors poses substantial challenge capability reactive oxygen species‐dependent PDT. Consequently, researches increasingly focus from type II I mechanism, which relies on radical production with less or no dependence. Despite significant progress development PSs, holistic understanding regarding design principles these molecules remains elusive. Specifically, electron transfer‐mediated are extensively studied years but is insufficiently addressed existing reviews. This review systematically summarizes advancements molecular rationales organic categorizing them into three key fundamental strategies: modulating PS charge distribution, singlet forbidden via low triplet excited state, accelerating formation inducing transfer. aims offer valuable insights advancement anti‐hypoxia

Language: Английский

Citations

0

The Current Advances in Design Strategy (Indirect Strategy and Direct Strategy) for Type‐I Photosensitizers DOI Creative Commons
Ning Ma,

Junjie Wang,

Hui Tang

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 25, 2024

Type-I photosensitizers (PSs) are among the most potential candidates for photodynamic therapy (PDT), as their low dependence on oxygen endow them with many advantages treating hypoxic tumor. However, of reported type-I PSs have a contingency molecular design, because electron transfer (ET) reaction is more difficult to achieve than energy (EET) process. Therefore, it urgent understand design mechanisms PSs. In this review, two ways PSs, i.e., inhibiting EET process (type-II) or enhancing ET (type-I), detailly explained. response, current strategies summarized from perspectives: indirect strategy (inhibiting process: reducing lowest triplet excited state (T

Language: Английский

Citations

0